-

Tubulis to Present at the 43rd Annual J.P. Morgan Healthcare Conference

MUNICH--(BUSINESS WIRE)--Tubulis today announced that its CEO and Co-founder Dominik Schumacher will present a company overview and update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Tuesday, January 14, 2025, at 9:00 am PST in the Golden Gate Room (32. Floor) at The Westin St. Francis.

About Tubulis

Tubulis generates uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. Our first NaPi2b-targeting program, TUB-040, is being evaluated in the clinic in ovarian and non-small cell lung cancer. The second candidate from our growing pipeline, TUB-030, targeting 5T4, is set to follow imminently. We will solidify our leadership position by continuing to innovate on all aspects of ADC design leveraging our proprietary platform technologies. Our goal is to expand the therapeutic potential of this drug class for our pipeline, our partners and for patients. Visit www.tubulis.com or follow us on LinkedIn.

Contacts

For Tubulis
Dominik Schumacher, CEO & Co-founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May, PhD
Phone: +49 171 185 56 82
Email: tubulis@trophic.eu

Industry:

Tubulis

Release Versions
English

Contacts

For Tubulis
Dominik Schumacher, CEO & Co-founder
Phone: +49 175 800 5594
Email: contact@tubulis.com

Media Requests for Tubulis
Trophic Communications
Stephanie May, PhD
Phone: +49 171 185 56 82
Email: tubulis@trophic.eu

Social Media Profiles
Tubulis on LinkedIn
Tubulis on Twitter
More News From Tubulis

Tubulis Announces Second Closing of Series C Bringing Total Raised to €344M (US $401M)

MUNICH--(BUSINESS WIRE)--Tubulis today announced a second and final closing of its Series C round totaling €344M (US $401M). The second closing brought in additional new investors Fidelity Management & Research Company, Janus Henderson Investors and Blackstone Multi-Asset Investing to a syndicate led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech...

Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025

MUNICH--(BUSINESS WIRE)--Tubulis today announced positive early clinical data from its NAPISTAR1-01 Phase I/IIa study (NCT06303505) in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Principal Investigator, Dr. Antonio González-Martín, Director Medical Oncology Department and Cancer Center Director at Clínica Universidad de Navarra, presented the results of Tubulis’ lead antibody-drug conjugate (ADC), TUB-040, in platinum-r...

Tubulis Raises €308 Million Series C to Accelerate Clinical Development of Lead ADC Candidate TUB-040 and Expand Pipeline

MUNICH--(BUSINESS WIRE)--Tubulis today announced the successful closing of a €308 million (USD 361 million) financing. The round was led by Venrock Healthcare Capital Partners with participation from additional new investors Wellington Management and Ascenta Capital. Existing investors who supported the Series C include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Part...
Back to Newsroom